Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Regadenoson Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A known ✓ | P29274 | 14/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 6/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Regadenoson Anhydrous SCHEMBL19387116 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL20128455 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL14131217 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL12958830 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL8925057 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL278152 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL13462149 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL15472806 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL6745611 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A | |
| Regadenoson Anhydrous SCHEMBL21710782 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301973-A1 | TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA | FLOHIL JACOB ARY (NL) | 2023-09-28 | — | — | US | claimed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | claimed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | claimed |
| EP-2789624-B1 | Stable solid forms of regadenoson | AMRI ITALY SRL (IT) | 2020-09-23 | — | — | EP | claimed |
| WO-2018106118-A1 | TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA | FLOHIL JACOB ARY (NL) | 2018-06-14 | — | — | WO | claimed |
| US-20170056381-A1 | PYRIDOXAMINE FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA AND RELATED BLOOD DISEASES | NANOMETICS LLC (US) | 2017-03-02 | — | — | US | claimed |
| US-9441006-B2 | Polymorph of 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]adenosine | FARMAK, A.S. (CZ) | 2016-09-13 | — | — | US | claimed |
| WO-2014177119-A1 | NEW POLYMORPH OF 2-[4-F(METHYLAMINO)CARBONYL]-1H-PYRAZOL-1-YL]ADENOSINE AND METHOD OF ITS PREPARATION | FARMAK, A.S. (CZ) | 2014-11-06 | — | — | WO | claimed |
| US-20140323712-A1 | POLYMORPH OF 2-[4-[(METHYLAMINO)CARBONYL]-1H-PYRAZOL-1-YL]ADENOSINE | FARMAK, A.S. (CZ) | 2014-10-30 | — | — | US | claimed |
| US-6403567-B1 | N-pyrazole A2A adenosine receptor agonists | CV THERAPEUTICS, INC. | 2002-06-11 | — | — | US | claimed |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| CN-119185343-A | Ruiganosheng in ultrasound application in cardiography | 南京瑞克卫生物医药有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | disclosed |
| US-20230248712-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES, INC. | 2023-08-10 | — | — | US | disclosed |
| WO-2006044856-A2 | USE OF A2A ADENOSINE RECEPTOR AGONISTS | CV THERAPEUITICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1492581-A1 | POLYMER COATING FOR MEDICAL DEVICES | CV THERAPEUTICS, INC. (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20030219562-A1 | Polymer coating for medical devices | CV THERAPEUTICS, INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003068289-A1 | POLYMER COATING FOR MEDICAL DEVICES | CV THERAPEUTICS, INC. (US) | 2003-08-21 | — | — | WO | disclosed |
| US-6403567-B1 | N-pyrazole A2A adenosine receptor agonists | CV THERAPEUTICS, INC. | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | ADORA2A 913/4885ADORA3 438/4885ADORA1 762/4885 |
| US-20230301973-A1 | TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA | ABCC2, SLC2A2, ABCB1 | ADORA2A 242/4885ADORA3 903/4885ADORA1 1385/4885 |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | ADORA2A 1801/4885ADORA3 3648/4885ADORA1 3168/4885 |
| US-20140323712-A1 | POLYMORPH OF 2-[4-[(METHYLAMINO)CARBONYL]-1H-PYRAZOL-1-YL]ADENOSINE | AMPD2, AMPD1, ADORA2A | ADORA2A 3/4885ADORA3 16/4885ADORA1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.